These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 28975009)

  • 1. Value Frameworks in Oncology: Comparative Analysis and Implications to the Pharmaceutical Industry.
    Slomiany M; Madhavan P; Kuehn M; Richardson S
    Am Health Drug Benefits; 2017 Jul; 10(5):253-260. PubMed ID: 28975009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncologists' Perceptions of Drug Affordability Using NCCN Evidence Blocks: Results from a National Survey.
    Shah-Manek B; Wong W; Ravelo A; DiBonaventura M
    J Manag Care Spec Pharm; 2018 Jun; 24(6):565-571. PubMed ID: 29451078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Approaches to Capturing Value in Oncology.
    Walter E
    Recent Results Cancer Res; 2019; 213():85-108. PubMed ID: 30543009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The correlation between the costs and clinical benefits of PD-1/PD-L1 inhibitors in malignant tumors: An evaluation based on ASCO and ESMO frameworks.
    Lin S; Huang Y; Dong L; Li M; Wang Y; Gu D; Wu W; Nian D; Luo S; Huang X; Xu X; Weng X
    Front Pharmacol; 2023; 14():1114304. PubMed ID: 36909180
    [No Abstract]   [Full Text] [Related]  

  • 5. Review of Recent US Value Frameworks-A Health Economics Approach: An ISPOR Special Task Force Report [6].
    Willke RJ; Neumann PJ; Garrison LP; Ramsey SD
    Value Health; 2018 Feb; 21(2):155-160. PubMed ID: 29477393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration.
    Molto C; Hwang TJ; Borrell M; Andres M; Gich I; Barnadas A; Amir E; Kesselheim AS; Tibau A
    Cancer; 2020 Oct; 126(19):4390-4399. PubMed ID: 32697362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Why Value Framework Assessments Arrive at Different Conclusions: A Multiple Myeloma Case Study.
    Westrich K; Buelt L; Dubois RW
    J Manag Care Spec Pharm; 2017 Jun; 23(6-a Suppl):S28-S33. PubMed ID: 28535102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validity and Reliability of Value Assessment Frameworks for New Cancer Drugs.
    Bentley TGK; Cohen JT; Elkin EB; Huynh J; Mukherjea A; Neville TH; Mei M; Copher R; Knoth R; Popescu I; Lee J; Zambrano JM; Broder MS
    Value Health; 2017 Feb; 20(2):200-205. PubMed ID: 28237195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three Sets of Case Studies Suggest Logic and Consistency Challenges with Value Frameworks.
    Cohen JT; Anderson JE; Neumann PJ
    Value Health; 2017 Feb; 20(2):193-199. PubMed ID: 28237194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Health Economics Approach to US Value Assessment Frameworks-Introduction: An ISPOR Special Task Force Report [1].
    Neumann PJ; Willke RJ; Garrison LP
    Value Health; 2018 Feb; 21(2):119-123. PubMed ID: 29477388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks.
    Del Paggio JC; Sullivan R; Schrag D; Hopman WM; Azariah B; Pramesh CS; Tannock IF; Booth CM
    Lancet Oncol; 2017 Jul; 18(7):887-894. PubMed ID: 28583794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value-based medicine in oncology: the importance of perspective in the emerging value frameworks.
    Campolina AG
    Clinics (Sao Paulo); 2018 Dec; 73(suppl 1):e470s. PubMed ID: 30540119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do the American Society of Clinical Oncology Value Framework and the European Society of Medical Oncology Magnitude of Clinical Benefit Scale Measure the Same Construct of Clinical Benefit?
    Cheng S; McDonald EJ; Cheung MC; Arciero VS; Qureshi M; Jiang D; Ezeife D; Sabharwal M; Chambers A; Han D; Leighl N; Sabarre KA; Chan KKW
    J Clin Oncol; 2017 Aug; 35(24):2764-2771. PubMed ID: 28574778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Building a Healthcare Alliance for Resourceful Medicine Offensive Against Neoplasms in Hematology Added Value Framework for Hematologic Malignancies: A Comparative Analysis of Existing Tools.
    Cerisoli F; Ali F; Bereczky T; Bolaños N; Bullinger L; Dhanasiri S; Gallagher J; Pérez SG; Geissler J; Guillevic Y; Harrison K; Naoum A; Portulano C; Rodríguez Vicente AE; Schulze-Rath R; Gómez GY; Sanz G; Hernández Rivas JM
    Value Health; 2022 Oct; 25(10):1760-1767. PubMed ID: 35595634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value assessment in oncology drugs: funding of drugs for metastatic breast cancer in Canada.
    Lemieux J; Audet S
    Curr Oncol; 2018 Jun; 25(Suppl 1):S161-S170. PubMed ID: 29910659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Descriptive comparison of hospital formulary decisions with published oncology valuation methods.
    Lam SW; Siebenaller C; Earl M; Hill BT; Kalaycio M; Rini B; Carraway HE; Leonard M; Sekeres MA
    J Oncol Pharm Pract; 2020 Jun; 26(4):891-905. PubMed ID: 31594520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Towards an evidence-informed value scale for surgical and radiation oncology: a multi-stakeholder perspective.
    Lievens Y; Audisio R; Banks I; Collette L; Grau C; Oliver K; Price R; Aggarwal A
    Lancet Oncol; 2019 Feb; 20(2):e112-e123. PubMed ID: 30712798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reliability of Oncology Value Framework Outputs: Concordance Between Independent Research Groups.
    Del Paggio JC; Cheng S; Booth CM; Cheung MC; Chan KKW
    JNCI Cancer Spectr; 2018 Jul; 2(3):pky050. PubMed ID: 31360865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Importance of Economic Perspective and Quantitative Approaches in Oncology Value Frameworks of Drug Selection and Shared Decision Making.
    Waldeck AR; Botteman MF; White RE; van Hout BA
    J Manag Care Spec Pharm; 2017 Jun; 23(6-a Suppl):S6-S12. PubMed ID: 28535105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.